Phaseline

Companies › Procter and Gamble

Procter and Gamble: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 4; Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Test Stannous Fluoride Dentifrice
Stannous fluoride (0.454%) dentifrice for anti-gingivitis and plaque reduction
SNF2Phase 4Gingivitis–
Sodium Monofluorophosphate Dentifrice–Phase 1Gingivitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06962956Test Stannous Fluoride DentifricePhase 1GingivitisGastroenterologyOct 2025
NCT06962956Sodium Monofluorophosphate DentifricePhase 1GingivitisGastroenterologyOct 2025
NCT07158112Test Stannous Fluoride DentifricePhase 4GingivitisGastroenterologyDec 2025

From the company's SEC filings

Cash of $15.4bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Targets

SNF2 (1)

Companies with the same targets

–

Companies built like this

Colgate Palmolive Healthgen Biotechnology NorthSea Therapeutics TRYP Therapeutics Green Cross Wellbeing

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.